Is InNexus Biotechnology, Inc. (IXSBF) a Buy, Sell, or Hold?
OTC : IXSBF
InNexus Biotechnology, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 5K
- Average Volume
- 2.03K
- Market Capitalization
- $12.63K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
Angela Giannoccaro
Medical - Pharmaceuticals
Healthcare
IXSBF
N/A
CA
USD
Liquidity Metrics
-0.66
0.00
0.00
0.00
0.00
Sales & Valuation
-$
0.00
0.00
-0.01
-0.02
Profitability
-$0.07
-$6.69M
0.00%
0.00%
189.86%
-194.61%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-21.61
2/9
-$9.28M
$3.16M
$9.58M
-$2.27M
Key Metrics (TTM)
$3.38M
0.00
-1.15
0.00
189.86%
0.00%
-49832.64%
-9112.84%
-1652 days
Company Executives
| Name | Title |
|---|---|
| Angela Giannoccaro | Chief Financial Officer |
| Jur T. Strobos | Vice President of Clinical & Regulatory Affairs and Member of Scientific Advisory Board |
Poll Results
No votes yet today — be the first to share your view!
About InNexus Biotechnology, Inc. (OTC:IXSBF) Stock
InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being de ... veloped for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Frequently Asked Questions
-
What is the current InNexus Biotechnology, Inc. (IXSBF) stock price?
-
InNexus Biotechnology, Inc.(OTC:IXSBF) stock price is $0.0001 in the last trading session. During the trading session, IXSBF stock reached the peak price of $0.0001 while $0.000001 was the lowest point it dropped to. The percentage change in IXSBF stock occurred in the recent session was 0.0% while the dollar amount for the price change in IXSBF stock was $0.
-
IXSBF's industry and sector of operation?
-
The OTC listed IXSBF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of IXSBF?
-
Angela Giannoccaro | Chief Financial Officer
Jur T. Strobos | Vice President of Clinical & Regulatory Affairs and Member of Scientific Advisory Board
|
|
| -
How many employees does IXSBF have?
-
Number of IXSBF employees currently stands at None. IXSBF operates from 1500 Royal Centre, Vancouver, None None, CA.
-
Link for IXSBF official website?
-
Official Website of IXSBF is: http://www.innexusbiotech.com/
-
How do I contact IXSBF?
-
IXSBF could be contacted at phone #None and can also be accessed through its website. IXSBF operates from 1500 Royal Centre, Vancouver, None None, CA.
-
How many shares of IXSBF are traded daily?
-
The average number of IXSBF shares traded daily for last 3 months was 2.03K.
-
What is the market cap of IXSBF currently?
-
The market value of IXSBF currently stands at $12.63K with its latest stock price at $0.0001